Infectious endocarditis
Conditions
Brief summary
The primary outcome is combined and consists of the following events within 6 months after randomization: a. Death. b. Septic embolization. c. Bacteraemia with the same microorganism. d. Heart surgery not planned at the time of randomization.
Detailed description
a. Expenses related to hospital care and other treatment of the condition. b. Length of hospital stay. c. Length of antibiotic tratment. d. Complications related to intravenous access.
Interventions
DRUGlösning
DRUGMeropenem Fresenius Kabi 1 g pulver till injektionsvätska eller infusionsvätska
DRUGCeftriaxon Fresenius Kabi 2 g pulver till infusionsvätska
DRUGBensylpenicillin Meda 3 g pulver till injektions/infusionsvätska
DRUGDoktacillin 1g respektive 2 g pulver till injektions/infusionsvätska
DRUGCefotaxim Stragen 1 g pulver till injektions- och infusionsvätska
DRUGCubicin 350 mg powder for solution for injection or infusion
Sponsors
Region Skane
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome is combined and consists of the following events within 6 months after randomization: a. Death. b. Septic embolization. c. Bacteraemia with the same microorganism. d. Heart surgery not planned at the time of randomization. | — |
Secondary
| Measure | Time frame |
|---|---|
| a. Expenses related to hospital care and other treatment of the condition. b. Length of hospital stay. c. Length of antibiotic tratment. d. Complications related to intravenous access. | — |
Countries
Sweden
Outcome results
None listed